Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Toxicities associated with brentuximab vedotin in pediatric and adolescent Hodgkin lymphoma

Kara Kelly • 5 Jun 2022
ASCO 2022
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin

Kara Kelly, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, provides an overview of the toxicities associated with brentuximab vedotin in adolescent and pediatric patients with Hodgkin lymphoma. Concerns of myelosuppression, infection risk and peripheral neuropathy which are associated with brentuximab vedotin administration in adults, is reduced in adolescent and pediatric populations. Dr Kelly discusses the next steps evaluating the use of brentuximab vedotin in pediatric settings, and highlights reduced radiotherapy as an area of unmet need in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Kara Kelly

1:14
Survival gap between adult and pediatric cases of Hodgkin lymphoma
Kara Kelly • 5 Jun 2022
1:36
The promise of brentuximab vedotin for the treatment of pediatric HL
Kara Kelly • 5 Jun 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals